Drug Profile
Research programme: HIV editing enzyme drugs - OyaGen
Alternative Names: HIV editing enzyme drugs research programme - OyaGenLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator OyaGen
- Class Peptides; Small molecules
- Mechanism of Action HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral, Injection)
- 25 Feb 2011 Preclinical development is ongoing in the US
- 14 Jan 2004 Preclinical trials in HIV infections treatment in USA (unspecified route)